Lobe Sciences Provides Update on L-130 Clinical Program
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 ...
Source: marketscreener.com
Page 2 - Lobe Sciences Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lobe Sciences Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lobe Sciences Ltd Today - Breaking & Trending Today
Lobe Sciences Provides Update on L-130 Clinical Program
Lobe Sciences Ltd. ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company's lead clinical program, L-130, a proprietary stabilized...
Source: lelezard.com
Lobe Sciences : Corporate Presentation Q3, 2023 -October 09, 2023 at 12:36 pm EDT
Disclaimer IMPORTANT NOTICE. This presentation is an overview of Lobe Sciences Ltd. and is for information purposes only and should not be...
Source: marketscreener.com
Lobe Sciences announces amendment to Altemia acquisition agreement
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) told investors that it signed an amendment to its April 18, 2023, share purchase agreement to acquire Altemia &...
Source: proactiveinvestors.com
Lobe Sciences appoints Mathew Lee as its next CFO
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced Mathew Lee as its new Chief Financial Officer. Lee is the president of Manning Lee Management Ltd, a...
Source: proactiveinvestors.com